Adma Biologics reported $41.09M in Sales Revenues for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Adamis Pharmaceuticals ADMP:US USD 1.51M 1.47M
Adma Biologics ADMA:US USD 41.09M 7.18M
Agile Therapeutics AGRX:US USD 3M 876K
Alnylam Pharmaceuticals ALNY:US USD 264.31M 39.49M
Biocryst Pharmaceuticals BCRX:US USD 75.83M 10.3M
Dynavax Technologies DVAX:US USD 167.74M 88.73M
Novavax NVAX:US USD 734.58M 548.65M
Takeda 4502:JP JPY 1T 29.84B